STOCK TITAN

ProKidney (PROK) Stock News, Jun-Nov 2023

PROK NASDAQ

ProKidney Corp. develops rilparencel, also described as REACT or Renal Autologous Cell Therapy, as an autologous cell therapy candidate for patients with advanced chronic kidney disease and diabetes. News about PROK centers on clinical data from REGEN-007, Phase 3 PROACT 1/REGEN-006 development, regulatory interactions with the FDA on the use of eGFR slope in an accelerated approval pathway, and scientific presentations in nephrology forums.

Company updates also cover quarterly and annual financial results, cash runway commentary, investor conference participation, and leadership additions tied to commercial planning for rilparencel.

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.16%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.68%
Tags
conferences
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.00%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.00%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.55%
Tags
none
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.50%
Tags
conferences
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.73%
Tags
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.96%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.65%
Tags
management clinical trial
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.69%
Tags
none

FAQ

What is the current stock price of ProKidney (PROK)?

ProKidney (PROK) last closed at $1.05.

What is the market cap of ProKidney (PROK)?

The market cap of ProKidney (PROK) is approximately $218.4M.